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KAJIAN ANALISIS, BIOLOGIKAL, FARMAKOKINETIK DAN 
KESTABILAN EKSTRAK Piper sarmentosum Roxb. DAN BEBERAPA 
KAJIAN TERPILIH EKSTRAK Orthosiphon stamineus Benth. 
 
 
ABSTRAK 
 
Tujuan kajian adalah untuk menjalankan kajian analisis dan biologi ke atas 
akar, batang, daun dan buah Piper sarmentosum dan daun Orthosiphon stamineus, 
farmakokinetik dan kajian kestabilan ke atas ekstrak etanol buah Piper sarmentosum. 
Bahan serbuk daripada bahagian yang berlainan Piper sarmentosum diekstrak 
menggunakan etanol dan air manakala daun diekstrak berjujukan menggunakan 
petroleum eter, kloroform dan metanol. Daun Orthosiphon stamineus diekstrak 
dengan metanol dan beberapa ekstrak lain diperolehi daripada sumber berlainan. 
Ekstrak kedua-dua tumbuhan dianalisa secara kualitatif dan kuantitatif menggunakan 
spektroskopi Inframerah Terubah Fourier (FTIR) dan spektroskopi 
Ultralembayung/Tampak (UV/Vis), kromatografi lapisan nipis prestasi tinggi 
(HPTLC) dan kromatografi cecair prestasi tinggi (HPLC). Ekstrak akueous dan 
etanol daripada perbagai bahagian Piper sarmentosum dikaji untuk aktiviti antioksida 
in vitro dan ekstrak yang mempunyai aktiviti baik, iaitu ekstrak etanol buah dan 
daun, dinilai secara in vivo bagi aktiviti antioksida dan perlindungan hepatik 
menggunakan model stress oksidatif teraruh CCl4. Ekstrak berjujukan daun Piper 
sarmentosum, ekstrak methanol berfraksi, ekstrak akueous Orthosiphon stamineus 
dan fraksinya dikaji untuk aktiviti antiangiogenik dan interaksi. Ekstrak etanol buah 
Piper sarmentosum dikaji untuk farmakokinetik dan kestabilan dipercepat dengan 
menggunakan pelitorin, sarmentin dan sarmentosin sebagai penanda. 
 
Analisis kualitatif menunjukkan kehadiran flavonoid dan alkaloid di dalam 
ekstrak etanol bahagian berbeza Piper sarmentosum manakala flavonoid dan 
 xxx
triterpena terdapat di dalam ekstrak Orthosiphon stamineus. Analisis kuantitatif 
berbagai ekstrak Piper sarmentosum menggunakan HPTLC menunjukkan jumlah 
berbeza-beza rutin (0.0004-0.0109 mg/g) dan narigenin (0.010-0.659 mg/g). Analisis 
HPTLC ekstrak berbagai Orthosiphon stamineus menunjukkan jumlah berbeza-beza 
asid betulinik (0.013-0.124 mg/g) dan sinensitin (0.470-1.335 mg/g). 
 
Kaedah HPLC baru dibangunkan, divalidasi dan digunakan untuk penentuan 
kuantitatif serentak rutin dan flavonon dalam ekstrak Piper sarmentosum yang 
menunjukkan amaun rutin antara 0.20-5.02 mg/g dan flavonon 0.32-15.32 mg/g. 
Kaedah HPLC lain dibangunkan, divalidasi dan digunakan untuk penentuan 
kuantitatif serentak pellitorin, sarmentin dan sarmentosin dalam ekstrak Piper 
sarmentosum yang menunjukkan amaun pellitorin antara 0.043-6.820 mg/g, 
sarmentin 0.006-0.420 mg/g dan sarmentosin 0.005-0.120 mg/g. Kaedah HPLC yang 
terdahulu untuk penentuan kuantitatif asid betulinik diperbaiki, divalidasi dan 
digunakan untuk analisis pelbagai jenis ekstrak Orthosiphon stamineus yang 
mempamerkan amaun asid betulinik antara 2.76-9.50 mg/g. 
 
Ekstrak etanol buah dan daun Piper sarmentosum mempamerkan aktiviti 
antioksida in vitro yang baik di dalam model DPPH dengan IC50 pada 25.87 dan 
23.66 ug/mL, masing-masing. Kedua-dua ekstrak menunjukkan aktiviti yang baik 
dalam model β-karotena linoleat. Aktiviti antioksida ekstrak didapati mempunyai 
korelasi dengan jumlah kandungan polifenol, flavonoid dan amida (P<0.05) 
 
Kajian ketoksikan akut oral ekstrak etanol buah dan daun Piper sarmentosum 
menunjukkan median dos kematian (LD50) melebihi 2000 mg/kg dalam tikus. 
 xxxi
Ekstrak kedua-dua bahagian dikaji in vivo untuk aktiviti antioksida dan perlindungan 
hepatik pada dua aras dos 250 dan 500 mg/kg. Kumpulan-kumpulan prarawat 
mempamerkan pengekalan signifikan aktiviti antioksida dan penanda fungsi hati 
berbanding dengan kumpulan kontrol negatif (CCl4) (P<0.05). 
 
Ekstrak kloroform daun Piper sarmentosum dan fraksi n-heksana ekstrak 
akueous Orthosiphon stamineus mempamerkan 100 dan 80% aktiviti antiangiogenik, 
masing-masing dengan IC50 pada 45 ug/mL dan IC50 pada 45 ug/mL. Amida yang 
diasingkan daripada buah Piper sarmentosum, pelitorin, sarmentin dan sarmentosin 
mempamerkan 30% aktiviti antiangiogenik manakala sebatian terasing daripada 
fraksi n- heksana Orthosiphon stamineus, asid betulik, oleanolik dan ursolik 
mempamerkan 100% aktiviti antiangiogenik. Dalam kajian sitotoksisiti, ekstrak 
kloroform dan fraksi n- heksana masing-masing menunjukkan IC50 pada 76.24 dan 
80 ug/mL, adalah lebih tinggi berbanding IC50 antiangiogenesis. 
 
Fraksi kloroform dan etil asetik ekstrak methanol daun Piper sarmentosum 
menunjukkan aktiviti antimikobakteria dengan kepekatan perencatan minimum 
(MIC) 3.12 ug/mL manakala fraksi n- heksana ekstrak akueous Orthosiphon 
stamineus menunjukkan aktiviti MIC 3.12 ug/mL. Dalam kajian interaksi, ekstrak 
dan fraksi kedua-dua tumbuhan tidak menunjukkan interaksi dengan isoniazid kerana 
indeks kepekatan perencatan fraksi (FICI) adalah >0.5. 
 
Kaedah HPLC baru telah dibangunkan, divalidasi dan digunakan untuk 
menentukan serentak pelitorin, sarmentin dan sarmentosin daripada plasma, urin, 
jirim najis dan tisu. Dalam kajian farmakokinetik ekstrak etanol buah Piper 
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sarmentosum dalam tikus, pelitorin dan sarmentin menunjukkan bioperolehan oral 
yang baik manakala sarmentosin tidak diserap secara oral dan dikumuhkan tidak 
berubah dalam najis. Pelitorin dan sarmentin mempamerkan activiti tisu berbeza dan 
dikumuhkan di dalam urin sebagai metabolit. 
 
Dalam kajian kestabilan dipercepat, anggaran hayat simpanan (t90) pelitorin, 
sarmentin dan sarmentosin adalah kira-kira 16 bulan pada 25oC. Penanda menuruti 
tindak balas tertib sifar dan kestabilannya didepati menurun pada suhu tinggi dan 
kelembapan relatif (RH). 
 
Kesimpulannya, kaedah HPLC yang dibangunkan adalah mudah dan senang 
dilakukan dan boleh digunakan untuk pempiawaian. Ekstrak Piper sarmentosum 
menjanjikan aktiviti antioksida dan perlindungan hepatik. Ekstrak kloroform Piper 
sarmentosum dan fraksi n-heksana ekstrak akueous Orthosiphon stamineus 
menjanjikan aktiviti antiangiogenik. Ekstrak kedua-dua tumbuhan tidak berinteraksi 
dengan isoniazid.  
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ANALYTICAL, BIOLOGICAL, PHARMACOKINETIC AND STABILITY 
STUDIES OF Piper sarmentosum Roxb. EXTRACTS AND SELECTED 
STUDIES OF Orthosiphon stamineus Benth. EXTRACTS 
 
ABSTRACT 
 
The study aimed to perform analytical and biological activity studies on root, 
stem, leaf and fruit of Piper sarmentosum and leaves of Orthosiphom stamineus, 
pharmacokinetic and stability studies on ethanol extract of fruit of Piper 
sarmentosum.  Powdered material of different parts of Piper sarmentosum was 
extracted using ethanol and water while leaves were also extracted sequentially using 
petroleum ether, chloroform and methanol. Leaves of Orthosiphom stamineus were 
extracted with methanol and few prepared extracts were obtained from different 
sources. The extracts of both the plants were analyzed qualitatively and 
quantitatively using Fourier Transform Infrared (FTIR) and ultraviolet/visible 
(UV/Vis) spectroscopy, high performance thin layer chromatography (HPTLC) and 
high performance liquid chromatography (HPLC).  Aqueous and ethanol extracts of 
different parts of Piper sarmentosum were investigated for in vitro antioxidant 
activity and the extracts having good activity namely fruit and leaf ethanol extracts 
were evaluated for in vivo antioxidant and hepatoprotective activity using CCl4 
induced oxidative stress model.  Sequential extracts of Piper sarmentosum leaf and 
fractions of the methanol extract, aqueous extract of Orthosiphom stamineus and its 
fractions were investigated for antiangiogenic and interaction studies. Ethanol extract 
of the fruit of Piper sarmentosum was investigated for pharmacokinetic and 
accelerated stability studies using pellitorine, sarmentine and sarmentosine as 
markers.  
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Qualitative analysis indicated the presence of flavonoids and alkaloids in 
ethanol extracts of different parts of Piper sarmentosum while flavonoids and 
triterpenes in extracts of Orthosiphom stamineus. Quantitative analysis of different 
extracts of Piper sarmentosum by HPTLC indicated varying amaunts of rutin 
(0.0004-0.0109 mg/g) and naringenin (0.010-0.659 mg/g). The HPTLC analysis of 
different extracts of Orthosiphon stamineus indicated varying amaunts of betulinic 
acid (0.013-0.124 mg/g) and sinensitin (0.470-1.335 mg/g).  
 
A new HPLC method was developed, validated and applied for the 
simultaneous quantification of rutin and flavonone in Piper sarmentosum extracts 
which indicated varying amaunt of rutin ranging 0.20-5.02 mg/g and flavonone 0.32-
15.32 mg/g. Another HPLC method was developed, validated and applied for the 
simultaneous quantification of pellitorine, sarmentine and sarmentosine in Piper 
sarmentosum extracts which indicated varying amaunts of pellitorine ranging 0.043-
6.820 mg/g, sarmentine 0.006-0.420 mg/g and sarmentosine 0.005-0.120 mg/g. A 
previously used HPLC method for the quantification of betulinic acid was improved, 
validated and applied to analyse different extracts of Orthosiphon stamineus which 
exhibited varying amaunts of betulinic acid ranging 2.76-9.50 mg/g. 
 
 
Ethanol extracts of the fruit and leaf of Piper sarmentosum exhibited good in 
vitro antioxidant activities in DPPH model with IC50 at 25.87 and 23.66 µg/mL, 
respectively. Both the extracts have also shown good activity in β-carotene linoleate 
model. The antioxidant activity of the extracts was found to be correlated with total 
content of polyphenolics, flavonoids and amides (P < 0.05). 
  
 xxxv
 Acute oral toxicity studies of the fruit and leaf ethanol extracts of Piper 
sarmentosum indicated median lethal dose (LD50) above 2000 mg/kg in rats. The 
extracts of both the parts were investigated for in vivo antioxidant and 
hepatoprotective activities in two dose levels 250 and 500 mg/kg. The pretreated 
groups exhibited significant preservation of antioxidant activity and liver function 
markers as compared to negative control (CCl4) group (P < 0.05). 
 
 
Chloroform extract of the leaf of Piper sarmentosum and n-hexane fraction of 
aqueous extract of Orthosiphon stamineus exhibited 100 and 80% antiangiogenic 
activity with IC50 at 45 µg/mL and IC50 at 45 µg/mL, respectively. Amides isolated 
from the fruit of Piper sarmentosum, pellitorine, sarmentine and sarmentosine, 
exhibited 30 % antiangiogenic activity while the isolated compounds from the n-
hexane fraction of Orthosiphon stamineus, betulinic, oleanolic and ursolic acids, 
exhibited 100% antiangiogenic activity. In cytotoxicity studies, the chloroform 
extract and the n-hexane fraction have shown IC50 at 76.24 and 80 µg/mL, 
respectively, which are higher as compared to IC50 of antiangiogenesis.  
 
Chloroform and ethyl acetate fractions of the leaf methanol extract of Piper 
sarmentosum have shown antimycobacterial activity with minimum inhibitory 
concentration (MIC) 3.12 µg/mL while n-hexane fraction of  aqueous extract of 
Orthosiphon stamineus has shown the activity MIC 3.12 µg/mL. In interaction 
studies, the extracts and the fraction of both the plants have not shown any 
interaction with isoniazid because fractional inhibitory concentration index (FICI) 
was found to be > 0.5. 
 
 
 xxxvi
A new HPLC method was developed, validated and applied for the 
simultaneous determination of pellitorine, sarmentine and sarmentosine from plasma, 
urine, fecal matter and tissues. In pharmacokinetic studies of the fruit ethanol extract 
of Piper sarmentosum in rats, pellitorine and sarmentine showed good oral 
bioavailability while sarmentosine was not absorbed orally and excreted unchanged 
in feces. Pellitorine and sarmentine exhibited different tissue affinities and were 
excreted in urine as metabolites. 
 
In accelerated stability studies, estimated shelf life (t90) of pellitorine, 
sarmentine and sarmentosine was approximately 16 months at 25 oC. The markers 
followed the zero order reaction and their stability was found to be decreasing at high 
temperature and relative humidity (RH). 
 
The results of the study indicates that the developed HPLC methods are 
simple, easy to perform and can be applied for standardization. Extracts of Piper 
sarmentosum have promising antioxidant and hepatoprotective activity. Chloroform 
extracts of Piper sarmentosum and n-hexane fraction of aqueous extract of 
Orthosiphon stamineus have promising antiangiogenic activity. The extracts of both 
the plants have no interaction with isoniazid. 
 1
CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
 
1.1 THERAPEUTIC POTENTIAL OF FLORA 
The use of natural flora in the treatment of different ailments is centuries old. 
The evidence of the use of natural products in therapeutics can be traced back for at least 
5000 years (Goldman, 2001). The development of modern drugs is owed to the 
traditional use of natural substances. About 40% of the new drugs approved in North 
America in a period of 1983-1994 were derived from natural compounds (Simmonds, 
2003). Approximately 70% of the new chemical entities reported from 1981-2006 
resulted from the study of natural products (Newman and Cragg, 2007). Documentation 
of more than 85000 plant species globally for medical use indicates the interest of 
scientists and healthcare professionals in natural products (Balunas and Kinghorn, 2005). 
 
The plants have played an important role in maintaining health by providing 
molecules and products to combat diseases. Many plants and plant based products are 
being used as folk remedies in the form of fresh or dried plant materials and in the form 
of extracts. According to the WHO report, 75% population of the world has therapeutic 
experience with herbal products (Dubey et al., 2004).  
 
In spite of many developments in synthetic chemistry, cultivation and utilization 
of medicinal plants is increasing due to their use as traditional medicine. Moreover, 
despite the development of various approaches for drug development, plants still are one 
of the best reservoirs of new structural entities. A single plant contains a large number of 
compounds which can be used as a starting material for the synthesis of novel drugs. 
Among 250,000 plant species, only a small percentage has been investigated for 
bioactive compounds (Prance, 1977). It means that the potential of plants as a source of 
new drugs has not explored completely. 
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Traditional medicine represents a vast array of therapies with proven benefits for 
the prevention and cure of different ailments. Nowadays, these are being used along with 
modern medicines in many countries. The combination of traditional and modern 
medicines is playing an important role in healthcare. Due to this fact herbal medicines 
are making a strong comeback in many countries (WHO, 2001). The increase in the 
popularity of herbal remedies is due to increase in the cost of treatment with modern 
medicines, fear of their side effects and new appreciation of natural remedies, which 
represents alternative healthcare movement. Due to this reason, the demand of herbal 
products has increased tremendously in the world market especially among ageing young 
generation, eagerly seeking preventive treatment of various diseases. 
 
The actual global market size of herbal products is difficult to assess because 
sale of these products is not regulated and accurate statistics are not available. Till 1988, 
only 14 of the WHO member countries regulated the sales of herbal products and since 
then, 53 countries were added in the list with another 42 in the process of developing 
relevant regulations by 2003 (Voigt, 2006). According to a survey conducted in 2004, 
more than one third of the American adults use alternative medicine (Voigt, 2006). This 
consumer driven movement has expanded the market of natural products significantly. 
The worldwide sale of the medicinal plants, crude extracts and finished products was 15 
billion US dollars in 1999 (Raskin et al., 2002), which increased up to 32 billion US 
dollars in 2002 (Dubey et al., 2004). According to the World Bank projection, with 
annual increase of 5-15%, the current market size of herbal products is about 60 billion 
US dollars per year (Voigt, 2006). 
 
The use of herbs varies from country to country and every country tends to have 
its own particular herbs. For example, products containing Echinacea or ginkgo are 
popular in Germany. Feverfew, garlic, ginseng, passiflora and valerian are used more in 
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the United Kingdom. The use of these remedies is primarily for the management or 
prevention of chronic age related diseases and to improve the quality and longevity of 
life. The pathophysiology of these conditions is completely unknown and for which 
presently available synthetic drugs are rarely preventive or curative (Mitscher et al., 
2000). 
 
The development of spectroscopic methods for the elucidation of chemical 
structure of naturally occurring compounds together with development of biological 
sciences have opened a new era to study structure activity relationship. These 
developments have made possible to prepare derivatives or synthetic analogues using 
natural compounds as models. 
 
1.2 ETHNOBOTANY OF MALAYSIA 
Malaysia is situated in the tropics, between 1 and 6 degree north and consists of 
East Malaysia (Sabah and Sarawak) in the northern part of the Borneo, bordering 
Indonesia and South China Sea and West Malaysia, peninsula south of Thailand. The 
region is mountainous with peaks rising up to 2000 m. The climate has characteristic 
high temperature and rainfall around the year. Temperature does not vary much from 
month to month and there is no significant variation in the daily temperature. 
 
The total area under the Malaysian rainforest is around 19.12 million hectares 
and it covers 58.1% of the land. This area is a habitat of more than 20000 plant species 
and out of which 2000 species are reported to have medicinal properties (Jaganath and 
Ng, 2000). 
 
Many Malaysians have broad traditional knowledge about folklore uses of plants 
and plant derived preparations. Malaysian population is a multi-ethnic and multi-cultural 
comprising of three main ethnic cultures, the Malays, the Chinese and the Indian. These 
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ethnic sects have intermixed for the past centuries but each ethnic sect has its own 
distinct healthcare system. The plants, which were brought by the Chinese and the 
Indians have adopted, naturalized and hybridized very well in the local conditions. A 
similar diversity of traditional medicine systems also exists, including the Malay, the 
Indian and the Chinese folk medicine. The three main races have their own traditions of 
treatment, traditional knowledge of medicinal plants and collection of herbs. A report on 
the utilization of plants in traditional medicine in peninsular Malaysia was published, 
describing the use of 543 remedies to cure various disorders (Burkhill, 1935). Another 
version was published on the Malay village medicine describing 650 plant species of 116 
families (Burkhill, 1966). In this publication, 20 species of Annonmaceae, 20 species of 
Zingiberaceae, 40 species of Rubiaceae, 54 species of Legunminosae and 932 species of 
Euphorbiaceae were reported as useful medicinal plants. 
 
The Malaysian flora is a huge reservoir of genetic diversity and a source of 
wealth in terms of chemicals that can be used in healthcare. There has been a great 
interest in the investigation of medicinal plants. The research is being carried out to 
develop modern drugs from local plants.  
 
1.3 PHYTOCHEMICAL ANALYSIS 
 Phytochemical analysis is concerned with chemical characterization of plant 
materials and includes qualitative and quantitative analysis. The former deals with the 
identification of constituents present in crude drugs while the later deals with the 
determination of how much of one or more substances are present in the crude drug. 
Furthermore, it also includes the development and validation of analytical techniques 
and isolation and characterization of characteristic compounds, which can be used as 
markers for standardization. Therefore, analytical studies are of prime importance to 
produce standardised formulations for preclinical and clinical studies. Unlike synthetic 
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compounds, analytical methods and standards are not adequate for herbal drugs, which is 
the main constraint of natural product industry. 
 
1.3.1 Standardisation 
More than 80% population of the developing countries relies on the use of 
herbal/traditional medicines in their primary healthcare because these are economical 
and time tested. The WHO (World Health Organization) encourages, recommends and 
promotes the use of traditional and herbal remedies in National Healthcare Program 
because these drugs are easily available at low cost, comparatively safer and people have 
faith in such remedies (Wani, 2007). Plant materials and herbal remedies have a 
substantial proportion in the global drug market. Therefore, an internationally recognized 
quality assessment of herbal products is necessary. The WHO in a number of resolutions 
has emphasized the need to ensure quality control of herbal products using modern 
analytical techniques because herbal products of well defined constituents are required 
for clinical trials. Therefore, to make herbal preparation a reliable and affordable 
medicine, the product must be standardized applying all the standards of quality control 
like any synthetic drug. Advances in chemical and biological techniques during the past 
50 years have resulted in scientific evidence to substantiate the use of herbal products 
and have enabled manufacturers to produce evidence based standardized products 
(Phillipson, 2003). 
 
Standardisation is a process to maintain consistency in claimed efficacy of a 
product and its batch-batch reproducibility. Standardisation of herbal preparations is a 
difficult task due to unavailability or inadequacy of standards and methods of analysis. 
Lack of standardisation is a biggest hindrance in the wider acceptance of herbal 
products. Moreover, it also prevents modernization or modification of production 
methods because there is no way to establish the equivalence between a product made by 
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modified and the original method. Standardised herbal products have several advantages 
as compared to crude extracts because it assures the identification that “the herb is what 
it is claimed to be”. 
 
In contrast to single entity based pharmaceuticals, most of the herbal remedies 
lack in scientific evidence and are only based on realm and myth. In order to bring 
botanical products in mainstream of pharmaceutical market, solid scientific evidence is 
needed to support the functionality claims of the products. The major challenges in terms 
of scientific standardisation to adhere to industry norms are variation in the source, 
unknown active ingredients, lack of safety evaluations, difficulty in quality control and 
unclear mechanism of actions (Wang and Ren, 2002). Therefore, it is imperative to 
analyze plant materials to prepare standardised herbal products. 
 
Unlike synthetic drugs, precise standardisation of herbal medicine is not easy due 
to unknown nature of the constituents. Synthetic drugs have well known constituents 
while the active components in many herbs are unknown. The use of markers helps in 
standardisation of herbal products. Markers were first classified into three main 
categories as active principles, active markers and analytical markers. Active principles 
are the constituents of the extract with proven activity. Active markers are the 
constituents which have known pharmacological activity and contribute to some extent 
to efficacy. However, their clinical efficacy may not be proven. Analytical markers are 
the constituents which are chosen when neither active principles nor active markers are 
available. Recently, markers have been classified into eight categories such as 
therapeutic components, bioactive components, synergistic components, characteristic 
components, main components, correlative components, toxic components and general 
components (Li et al., 2008). The markers help in positive identification or 
standardisation of extracts (United States Pharmacopoeia, 2005). The identification of 
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active principles/active markers of herbal products would be the best solution but when 
these are not possible, standardisation can be based on markers of different chemical 
classes to ensure that the extract is more representative of the original plant material. 
 
Standardisation of herbal products can be divided into two categories. First, an 
active constituent extract, where biochemical principles are known and have therapeutic 
values, and second, a marker extract, where the active principle is not known and a 
characteristic compound is used as a marker to assess the presence of other biochemical 
compounds that make the extract active (Tierra, 2008). In active constituent extracts, the 
known biochemical compound(s) is isolated. But this type of standardisation has 
limitations that only isolated compound(s) is considered, ignoring the whole constituents 
of the herb which may have synergistic or buffering activities to reduce the side effects. 
In marker extract standardisation, where active principle is not known, partly known or 
mix preparation containing many crude drugs or extracts, the whole formulation is 
considered active in the presence of all plant constituents. In this type of products, a 
single isolated compound would not be used as a marker because it is not unique enough 
to any one plant. The standardisation of herbal drug(s) is not mere an analytical 
operation which ends with the identification and assay of the active principle(s) rather it 
embodies total information and controls which are necessary to insure consistency in 
composition. Therefore, it is necessary to use all possible means of standardisation like 
TLC, HPLC and other related techniques to quantify active constituents and other 
components of the extract such as total content of primary and secondary metabolites. 
 
Metabolomic fingerprint profiling is an alternative way to standardize herbal 
products. Metabolomics, a system of cell biology, comprise of all the compounds other 
than proteins, deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). Metabolomics, 
detect, quantify and catalogue the time related metabolic processes of an integrated 
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biological system under specified conditions (Zhou et al., 2006). Metabolomic 
fingerprints are unique patterns, which indicate the presence of particular molecules 
based on specialized analytical techniques and are extremely useful to identify active 
components, contaminants and other chemicals present in herbal products (Fan et al., 
2006). 
 
Many international authorities and agencies including the World Health 
Organization, the European Agency for Evaluation of Medicinal Products and the 
European Scientific Cooperation of Phytomedicine, the US Agency for Healthcare 
Policy and Research and the European Pharmacopoeia Commission have started creating 
a new mechanism for quality control and standardisation of botanical medicines. A 
botanical formulation is now regarded as active substance in its entity whether or not the 
constituents with therapeutic activity are known. This is a major step in the development 
of new generation of standardized herbal medicines. Several spectroscopic and 
chromatographic techniques like UV, FTIR, TLC, HPLC, LC/GC-MS and NMR are 
used to obtain fingerprints. The fingerprints in combination with chemometrics provide 
effective tool of identification, classification and discrimination (Sherma and Fried, 
2003). The characterization of metabolic profiles not only helps in identification of 
active constituents but also improve the knowledge about efficacy, safety and 
complexity of a given therapeutic combination (Liu and Yang, 2006). Therefore, 
analytical studies on herbal drugs are very important to fill the big gap between 
indigenous herbal practices and contemporary medical sciences. 
 
1.3.2 Development and validation of analytical methods 
Great care must be taken that accurate results are obtained in an analytical 
procedure. Two types of error, random and systemic, may occur. Every measurement has 
some imprecision associated with it which results in random distribution of results. The 
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method should be designed in such a way to narrow the range of random errors. 
Systemic error is an error that biases a result in one direction. New developed analytical 
method must be validated to get accurate results. 
 
1.3.2.1 Validation 
According to FDA guidelines on process validation (FDA, 1987), validation is 
the assessment of a process or instrument to assure that the process and instrument is 
suitable for its intended use. Validation enables an efficient and productive use of the 
process and instrumental variables. The objective of validation of HPTLC/HPLC method 
is to demonstrate that the method is suitable for quantification of analyte under 
prevailing experimental conditions. A new method development, change in the 
operators, laboratory and equipments than the one in previous method require validation. 
A typical validation of the method is given as follows: 
 
1.3.2.1a Linearity and calibration curves 
Linearity is the ability of the method to obtain test results that are directly 
proportional, without or after mathematical transformation to the analyte’s concentration 
within a given range (United States Pharmacopoeia, 1999). The range is established by 
confirming that the analytical procedure provides an acceptable degree of linearity when 
applied to samples containing amounts of analyte within or at the extremes of the 
specified range of analytical procedure. 
 
Linearity of the method is evaluated by plotting concentration versus peak 
area/height. Each standard is analyzed in triplicate. Calibration curves are constructed on 
five data points and linearity is evaluated by correlation coefficient and standard 
deviation. Standard curves are used to get linear regression equation, which is obtained 
in the form given as follows: 
Y = mx + b…………………1.1 
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Where Y is the peak area/height, m is the slope of the standard curve, x is the 
concentration of analyte and b is the y-intercept of the line of standard curve. 
 
1.3.2.1b Precision 
Precision is a measure of the degree of repeatability of an analytical method 
under normal operation and is expressed in relative standard deviation (Ott and 
Longnecker, 2001). Precision can also be defined as the degree of agreement among 
individual results when analytical method is applied repeatedly to a homogenous sample 
(United States Pharmacopoeia, 2005). The precision in different official books has 
recently been reviewed (Walter et al., 2008). Precision can be subdivided into 
repeatability, intermediate precision, and reproducibility. 
 
 
Repeatability is the results of the method operating over a short time interval 
under the same conditions (inter-assay precision). It is determined from 3-5 replicate at 3 
different concentrations i.e. low, medium and high covering the expected concentration 
range of analyte (United States Pharmacopoeia, 1999; ICH, 2005). Intermediate 
precision arises from within laboratory variations due to random events such as different 
days, equipment, columns, reagents, etc. The experiment is design carefully in 
determining intermediate precision to monitor the possible effects of the individual 
variables. Reproducibility is assessed by means of an inter-laboratory trial and measured 
as relative standard deviation (RSD) or confidence interval (CI). 
 
1.3.2.1c Capacity factor 
Capacity factor is an important parameter used widely to describe migration rate 
of a solute in a column. It is denoted by (kَ) and is calculated by using following 
equation. 
k َ= (tR – tM) / tM……………..1.2 
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Where tR is the peak retention time and tM is the solvent retention time and is also called 
dead time. 
 
1.3.2.1d Resolution 
 Resolution is a quantitative measure of the ability of a column to separate two 
analytes. It is denoted by “Rs” and given by the following expression. 
R = 2 (tR2 - tR1) / w1 + w2 …………….1.3 
Where tR1 is the retention time of first peak, tR2 is the retention time of the second peak, 
w1 is peak width of peak 1 and w2 is peak width of peak 2. 
 
1.3.2.1e Accuracy 
Accuracy is degree of agreement between true values of analyte in sample and 
the observed value by the method (ICH, 2005). FDA recommends establishment of 
accuracy by minimum of 5 determinations for at least across the 3 levels (low, medium 
and high) in the range of expected concentrations. The accuracy is acceptable if the 
agreement of true and observed values is less than 15%. It is determined as the percent of 
analyte recovered by analytical method after spiking samples in a blind study. 
 
1.3.2.1f Sensitivity 
Sensitivity of the method is evaluated by the limit of detection (LOD) and limit 
of quantification (LOQ). The limit of detection (LOD) is the lowest concentration of an 
analyte in a sample that can be detected, but can not inevitably be quantified. The limit 
of quantification (LOQ) is the lowest concentration of an analyte in a sample that can be 
determined with acceptable precision and accuracy under the stated operational 
conditions of the method. The LOQ is verified by analyzing the standard 6 times at the 
LOQ concentration. Various approaches are available to determine the LOD. Usually 
used equations for the determination of LOD and LOQ (Stewart and Ebel, 2000) are 
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given as follows: 
LOD = 3.3σ / S………………1.4 
LOQ = 10 σ / S…………….1.5 
Where σ is the standard deviation of intercept of six standard curves and S is the mean 
slope of the standard curves. 
 
1.3.2.1g Specificity and system suitability 
Specificity is a measure of the degree of interference from such entities as blank 
plasma, other active ingredients, excipients, impurities and degradation products. 
Specificity ensures that peak response of an analyte is due to its own and there is no co-
elution (Vessman, 1996). System suitability is a test used to verify that the precision and 
accuracy are adequate for analysis to be done (United States Pharmacopoeia, 2005). 
 
1.3.2.1h Peak purity 
Peak purity is determined by spiking a solution of the extract with standard 
solution of the marker. The spiked solution and untreated solution are analyzed to 
determine the peak overlap of the obtained chromatograms. Peak purity is further 
established by using Photodiode Array (PDA), LC/GC-MS. The molecular ion of the 
mass spectrum of the peak of standard is compared with corresponding peak of the 
sample. In HPLTC, peak purity is determined by scanning the spots in a range of 700-
200 nm and spectra of the standards and sample are compared. 
 
1.3.2.1i Robustness 
Robustness, a measure of method reliability, is the capacity of a method to 
remain unaffected after small deliberate variations in method parameters. The robustness 
of the method is evaluated by varying method parameters such as percent mobile phase 
proportions, pH, ionic strength and temperature etc., and determining the effect (if any) 
on the results. If the results or other measurements are susceptible to variations in 
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method parameters, then these parameters should be controlled adequately. 
 
1.4 THE DISCOVERY OF HERBAL DRUGS 
Two approaches are being used to verify the claims of traditional medicine 
scientifically and to develop new drugs, which would be acceptable to modern system of 
medicine (Patil, 2003). The first approach involves direct clinical trials of commonly 
used traditional remedies followed by chemical and pharmacological studies. The second 
approach involves broad spectrum screening of individual plants followed by chemical, 
pharmacological, preclinical and clinical drug development studies. 
 
1.4.1 Phytochemical and taxonomical screening 
There are many reports in the literature on the screening of randomly collected 
plants from various geographical localities for a group of compounds. Data derived from 
such screening reports show little value in the discovery of active natural products. 
Another approach to search biologically active compounds in plants is to consider the 
taxa in which known useful drugs or derivatives occur. This is not much exciting path to 
follow in drug development, if novel agents are desired. However, it leads to identify 
new indigenous sources of known useful drugs which may lower the cost of drugs. 
 
1.4.2 In vitro biological studies 
Extracts of the plants are subjected to preliminary screening for biological 
activity using in vitro or ex vivo models. After preliminary screening, extracts having 
significant activity are further investigated for pharmacological activities using suitable 
models. The active extracts are also subjected to assay guided isolation for pure 
compounds, which may serve as potent drug(s) or drug prototype(s). 
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1.4.3 In vivo biological studies 
The extracts or pure compounds having significant in vitro activity are further 
investigated using suitable animal models. Before in vivo studies, plant materials are 
evaluated for toxicity to calculate suitable dose. The action of the drug in the living 
system is not only dependent on pharmacodynamics but also on pharmacokinetics. 
Animal studies are performed using suitable controls and positive controls. 
 
1.4.4 Pharmacokinetic studies 
Pharmacokinetics is defined as the action of body on the drug and it includes 
absorption, distribution, metabolism and excretion. It offers means to measure the 
amount of drug in blood stream, at the site of action and extent of the release of drug 
substance from a dosage form. Study of pharmacokinetic parameters has applications in 
toxicology (drug exposure) and biopharmaceutics (bioavailability and bioequivalence). 
The literature on pharmacokinetic studies of herbs is not sufficient due to a number of 
factors including lack of studies and scarce reporting.  
 
Pharmacokinetics data of herbs is also useful to understand herb-drug 
interactions. Furthermore, it may provide valuable information which may be helpful in 
prescribing herbal products safely and effectively. It may also enable us to make useful 
predictions regarding possible interactions between herbal remedies and conventional 
pharmaceuticals. 
 
Since longtime, natural product scientists have been studying the 
pharmacodynamics, actions of the herbs on the body, but less attention has been paid to 
study the effects of the body on herbal products. The action of the drug depends on the 
rate and extent of active components at the site of action which are monitored by 
pharmacokinetic parameters. 
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1.5 STABILITY STUDIES 
Stability is defined as the time during which a drug retains its chemical integrity 
and labeled potency within the specified limits. The stability of a pharmaceutical 
preparation is its degree of resistance to chemical and physical changes. A product 
should be consistent in efficacy and claimed potency or may change only within the 
limits specified by legal provisions until the date of expiry (Racz, 1989). Stability is one 
of the most important factors which determine whether a compound or a mixture of 
compounds can be developed into a pharmaceutical product. Stability studies provide 
evidences on how the quality of a drug substance varies with the passage of time under 
the influence of environmental factors (WHO, 1996). Stability studies before developing 
a dosage form are the first quantitative assessment of chemical stability of a new product 
and its possible formulation. Stability studies are used to recommend storage conditions 
and predict shelf life of medicinal products. 
 
 
The stability studies are essential for three main reasons. First, patient safety by 
assuring that the patient receives a uniform dose of drug throughout the shelf life of a 
product. Second, legal requirements concerning about identity, strength, purity and 
quality of a drug. Third is to prevent economic repercussions in developing and 
marketing an unstable product. The stability of a product is influenced by a number of 
factors, which may be classified into two main categories, physical and chemical factors. 
 
1.5.1 Physical factors effecting stability 
1.5.1.1 Temperature 
Temperature increases the rate of degradation of active ingredients due to the 
increase in kinetic energy, which increases the number of colliding molecules. The 
decomposition usually increases by two to three times for every 10 °C rise in 
temperature. Therefore, it is important to be aware about it while storing raw material 
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and in production of a product especially when heating is required. It is particularly 
important in case of thermolabile and volatile constituents. 
 
 
1.5.1.2 Moisture 
Moisture content increases the rate of decomposition and makes the product 
susceptible to hydrolysis. In case of herbal crude powders/extracts, it allows the growth 
of microbes which not only deteriorate the constituents but may produce toxic 
substances. 
 
1.5.1.3 Light 
There are many reports about the effect of sunlight on the stability of 
pharmaceutical products (Tonnesen, 2004). Sunlight being a form of energy can initiate 
and accelerates decomposition. Photolabile constituents of extracts deteriorate on 
exposure to sunlight (Rawlins, 1977; Pugh, 2002). 
 
1.5.2 Chemical factors effecting stability 
The constituents of extracts like other pharmaceuticals also undergo chemical 
degradation with the passage of time. The chemical degradation is further classified as 
follows: 
 
1.5.2.1 Hydrolysis 
Hydrolysis, reaction of the compound with water, is the most common cause of 
drug degradation (Waterman et al., 2002). It is considered to be a major cause of 
deterioration of drugs especially for aqueous based preparations. 
 
1.5.2.2 Oxidation 
Oxidation of a compound is defined as the removal of an electropositive atom, 
radical or electron, or addition of an electronegative atom, radical or electron. 
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Decomposition of pharmaceutical preparation due to oxidation is nearly as probable as 
that of hydrolysis. The rate of oxidation is temperature dependent. For example 
peroxidation of fatty acids, break down of fatty acids into aldehydes and ketones, 
accelerates as the temperatures exceeds 50 °C (Rawlins, 1977). 
 
1.5.2.3 Isomerisation and polymerisation 
Polymerization is the addition of similar molecules whereas isomerisation is the 
change in isomeric forms. These phenomena change the biological activity of 
compounds. 
 
The stability study of pharmaceuticals performed at exaggerated conditions is 
called accelerated stability. Accelerated stability study is performed for fast prediction of 
stability. 
 
1.6 Accelerated stability 
The test for examining the quality and potency of a product at suitable time 
intervals is conducted for a period corresponding to the normal time that the product is 
likely to remain in stock or in use. Degradation is usually slow at room temperature and 
shelf life may go up to several years. Since the period can be as long as two years, 
stability testing for this type will be time consuming and expensive. Therefore, 
accelerated stability testing is devised for rapid prediction of long term stability of a 
product. Though stability of drugs at room temperature is of primary interest, stability 
study at room temperature would take too long to be useful as a screening procedure for 
new formulations. Therefore, stability studies are conducted at elevated temperatures and 
the data is evaluated by applying Arrhenius equation (Sungthongjeen, 2004). 
 
A prediction of shelf life (t90), a time in which a product retains 90% of its 
original potency, may be made by accelerating the decomposition process and 
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extrapolating the results to normal storage conditions. For this reason stability tests are 
often performed under exaggerated conditions (elevated temperatures) to accelerate 
degradation process in order to get a fast stability prediction. Application of the 
principles of chemical kinetics on the results of accelerated stability tests enables us to 
make prediction about the shelf life of a product at normal temperature. 
 
Keeping in view the therapeutic importance of natural products, two local plants 
having significant potential of commercialization were selected to perform analytical 
work to standardize their extracts. The standardised extracts were then used to perform 
biological, pharmacokinetic and stability studies. 
 
1.7 LITERATURE REVIEW OF Piper sarmentosum 
Scientific name: Piper sarmentosum Roxburgh 
(Piper Latin name of Pepper and sarmentosum means twiggy/ with long slender runners) 
Local Name: Kadok 
Common name: Daun Kadok, Chau pulu, Jia ju 
Family: Piperaceae 
Synonyms: Chavica hainana DC.; Chavica sarmentosa (Roxburgh) Miq.; Piper 
alispicum DC.; Piper brevicaule DC.; Piper gymnostachyum DC.; Piper lolot DC.; Piper 
pierrei DC.; Piper saigonese DC. 
 
1.7.1 Botanical description 
The plant is herbaceous shrub, may be creeping along the ground or erect. The 
plant is usually found as a weed in villages under shady places (Hsuan, 1990) and the 
leaves are heart shaped (Wee, 1992). It grows up to 50-60 cm and is found in Cambodia, 
Laos, Philippines, Burma, Thailand, Malaysia, Vietnam and China. The leaves are 
simple, alternate and estipulate. The blade is lanceolate-ellipitical 10 cm X 5 -14 cm X 6 
-9.9 cm X 3.4 -12 cm X 2 cm, acuminate at the apex, round at the base, with two pairs of 
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secondary nerves. The florescences are 5 mm long nerves. The fruit is green and red with 
4 mm X 3 mm drupes (Wiart, 2006). The plant has a characteristic pungent odor (Hsuan, 
1990; Wee, 1992). 
 
1.7.2 Ethnopharmacology 
The plant is well known in South East Asian countries due to its medicinal 
properties. In the Chinese traditional treatment system, leaves of the plant are used to 
treat fever and indigestion (Wee, 1992) and roots are used to relieve toothaches (Duke 
and Ayensu, 1985; Toong and Wong, 1989; Wee, 1992). Roots are also used to treat 
dermatomycoses, coughing and pleurisy (Perry, 1981; Duke and Ayensu, 1985; Toong 
and Wong, 1989). In Malaysia and southern parts of Thailand, leaves are used externally 
to sooth headaches. In Indonesia, roots are chewed for cough, asthma and toothaches and 
leaves are also used to mitigate chest pain (Wiart, 2006). The fruit is used as an 
expectorant (Pongboonrod, 1976; Toong and Wong, 1989). 
 
1.7.3 Review of chemical constituents 
Main constituents of the plant are amide alkaloids, phenylpropanoids, pyrones, 
flavonoids, sterols and neolignans etc. More than 67 compounds have been separated 
and identified from the essential oil of Piper sarmentosum. The main compounds were 2, 
4, 5-trimethoxy-1-propenylbenzene 23.20%, cis-caryophyllene 13.33%, 1, 2-dimethoxy-
4-(1-propenyl)-benzene 12.63%, 1, 3-benzodioxole-4-methoxy-6-(2-propenyl) 5.71% 
and delta-cadinene 3.03% (Song et al., 2006). In an other study, the main components of 
the essential oil obtained from leaves of the plant were 10-Epi-γ-eudesmol 21.0%, α-
cadenine 18.8%, seychellene 12.6% and (E, E)-farnesol 10.5% (Chieng et al., 2005).  
The chemical constituents identified in this plant are given in Table-1 and structures of 
some chemical constituents are given in Fig. 1.1. 
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Table 1.1 Chemical constituents of Piper sarmentosum 
Constituents Reference 
Pellitorine [1] Thitima et al., 2004 
Likhitwitayawuid et al., 1988 
Tutiwachwuttikul et al., 2006 
Guineensine [2] Thitima et al., 2004 
Tutiwachwuttikul et al., 2006 
Brachystamide B [3] Thitima et al., 2004 
Tutiwachwuttikul et al., 2006 
Sarmentine [4] Thitima et al., 2004 
Tutiwachwuttikul et al., 2006 
Likhitwitayawuid et al., 1988 
Brachyamide B [5] Thitima et al., 2004 
1-piperettyl pyrrolidine [6] Thitima et al., 2004 
3,4,5-trimethoxycinnamoyl pyrrolidine [7] Thitima et al., 2004 
Sarmentosine [8] Thitima et al., 2004 
Tutiwachwuttikul et al., 2006 
Likhitwitayawuid et al., 1988 
(+) asarinin [9] 
 
Thitima et al., 2004 
Sesamin [10] 
 
Thitima et al., 2004 
Tutiwachwuttikul et al., 2006 
N-[9-(3,4-methylenedioxyphenyl)-2E,4E,8E-
nonatrienoyl] pyrrolidine [11] 
Tutiwachwuttikul et al., 2006 
Methyl piperate [12] Thitima et al., 2004 
β- sitosterol [13] Thitima et al., 2004 
Tutiwachwuttikul et al., 2006 
Likhitwitayawuid et al., 1988 
Niamsa et al., 1983 
Stigmasterol [14] Thitima et al., 2004 
Aromatic alkene [15] Tutiwachwuttikul et al., 2006 
1-allyl-2-methoxy-4,5-metylenedioxybenzene [16] Tutiwachwuttikul et al., 2006 
Masuda et al., 1991 
Sarmentide C [17] Tutiwachwuttikul et al., 2006 
Pyrrole amide [18] Tutiwachwuttikul et al., 2006 
Sarmentamide A [19] Tutiwachwuttikul et al., 2006 
Sarmentamide B [20] Tutiwachwuttikul et al., 2006 
  
1-(3,4-methyllenedioxyphenyl)-1E-tetradecene Thitima et al., 2004 
Horsfieldin [21] Tutiwachwuttikul et al., 2006 
N-(2-methylbutyl)-2E,4E-decadienamide  Stoehr et al., 1999 
Naringenin [22] Vimala et al., 2003 
Cis- caryophyllene Song et al., 2006 
Hydrocinnamic acid [23] Niamsa et al., 1983 
α-asarone [24] Song et al., 2006 
Likhitwitayawuid et al., 1988 
Asaraldehyde [25] Likhitwitayawuid et al., 1988 
1-(3,4-methylenedioxyphenyl)-1E-tetradecene Likhitwitayawuid et al., 1988 
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2,4,5-trimethoxy- 1-propenylbenzene [26] Song et al., 2006 
1- allyl- 2,4,5-trimethoxybenzene [27] Masuda et al., 1991 
1-(1E-propenyl)-2,4,5- trimethoxybenzene  Masuda et al., 1991 
1,2-dimethoxy-4-(1-propenyl)-benzene [28] Song et al., 2006 
1-allyl-2-methoxy-3,4-methylenedioxybenzene [29] Masuda et al., 1991 
1,3-benzodioxole-4-methoxy-6-(2- 
propenyl)  
Song et al., 2006 
10-Epi-γ-eudesmol [30] Chieng et al., 2005 
α-cadinene [31] Chieng et al., 2005 
Seychellene [32] Chieng et al., 2005 
Delta- cadinene [33] Song et al., 2006 
(E, E)-farnesol [34] Chieng et al., 2005 
Numbers in square brackets indicate the structure  
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Pellitorine [1] 
Guineensine [2] 
Brachystamide B [3] 
Sarmentine [4] 
Brachyamide B [5] 
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Sarmentosine [8] 
1-piperettyl pyrrolidine [6] 
3,4,5 trimethoxy cinnamoyl pyrrolidine [7] 
 
Asarinin [9] 
Sesamin [10] 
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N-(3,4-methylenedioxyphenyl)-2E,4E,8E-nanotrienoyl [11] 
Methyl piperate [12] 
 
β-sitosterol [13] 
Stigmasterol [14] 
Aromatic alkene [15] 
1-allyl 2-methoxy-4, 5 methylene  
dioxybenzene [16] 
Sarmentamide C [17] 
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Pyrrol amide [18] 
 
 
Sarmentamide A [19] 
Sarmentamide B [20} 
Horsfieldin [21] 
Hydrocinnamic acid [23] 
α asarone [24] 
Asaraldehyde [25] 
Naringenin [22] 
O C H 3
O C H 3
C H 3 O
C H = C H C H 3
